Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 874-882

  Mukovozov, Ilya ^a   Sabljic, Thomas ^a   Hortelano, Gonzalo ^a   Ofosu, Frederick A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Immunogenicity; Recombinant human proteins; Therapeutic proteins

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; INFLIXIMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT HUMAN INSULIN;

BINDING AFFINITY; CROHN DISEASE; DNA SEQUENCE; DRUG ACTIVITY; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CHEMISTRY, PHARMACEUTICAL; CLONING, MOLECULAR; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG CONTAMINATION; DRUG STABILITY; DRUG STORAGE; HUMANS; POLYETHYLENE GLYCOLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 43949122899     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-11-0654     Document Type: Review

References (158)

1. Crommelin DJ, Storm G, Verrijk R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003; 266: 3-16.
2. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 2006; 24: 769-776.
3. Shankar G, Pendley C, Stein K-E. A risk-based bioanalytic strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007; 25: 555-561.
4. Sharma B. Immunogenicity of therapeutic proteins. Part 1: Impact of product handling. Biotechnol Advan 2007; 25: 310-317.
5. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 2003; 61: 11-12.
6. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16: 155-165.
7. Takano K, Shizume K. Clinical experience with somatrem in Japan. Acta Paediatr Scand Suppl 1986; 325: 19-24.
8. Suh BK, Jorgensen EV, Root AW. Facilitation of the growth. J Pediatr Endocrinol Metab 1995; 8: 97-102.
9. Jacquemin MG, Saint-Remy JM. Factor VIII immunogenicity. Haemophilia 1998; 4: 552-557.
10. Peces R, de la Torre M, Alcazar R, et al. Antibodies against Recombinant Human Erythropoietin in a Patient with Erythropoietin-Resistant Anemia. N Engl J Med 1996; 335: 523-524.
11. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology derived proteins as active substance: non-clinical and clinical issues. Online 2006. Available at: http://www.emea.eu.int/pdfs/human/biosimilar/4283205en.pdf.
12. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002; 3: 349-360.
13. Center for Biologics Evaluation and Review. Product Approval Information - Licensing Action, Etanercept. U.S. Food & Drug Administration. Online 2003. Available at: http://www.fda.gov/cder/foi/label/2003/etanimm060503LB.pdf.
14. Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Net 2001; 12: 56-61.
15. Gribben JG, Devereu S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990; 335: 434-437.
16. Antonelli G, Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin and Exper Immunol 1996; 104: 384-387.
17. Zang YC, Ynag D, Hong J, et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 2000; 55: 397-404.
18. Dharnidharka VR, Takemoto C, Ewenstein BM, et al. Membranous glomerulonephritis and nephrosis post factor. Pediatr Nephrol 1998; 12: 654-657.
19. Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating a-glucosidase replacement. Pediatrics 2004; 114: e532-e535.
20. Figlin RA and Itri LM. Anti-interferon antibodies: A perspective. Sem Hematol 1988; 25: 9-15.
21. Ryff JC, Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends in Pharmacol Sci 2002; 23: 254-256.
22. Rosenschein U, Lenz R, Radnay J, et al. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr J Med Sci 1991; 27: 541-545.
23. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to hrombopoietin. Blood 2001; 98: 3241-3248.
24. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrology Dialysis Transplant 2002; 17: 42-47.
25. Lim LC. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology 2005; 10: 255-259.
26. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475.
27. Gershon SK, Luksenburg H, Cote TR, et al. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-1586.
28. Ragnhammar P, Wadhwa M. Neutralizing antibodies to granulocytemacrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med Oncol 1996; 13: 161-166.
29. Prümmer O. Treatment-induced antibodies to interleukin-2. Biotherapy 1997; 10: 15-24.
30. Hartung HP, Munschauer F, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 1995; 12: 588-601.
31. Öberg K, Alm G, Norheim L, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: Development of neutralizing interferon antibodies and possible loss of antitumor activity. Natl Cancer Inst 1989; 81: 531-535.
32. Sorensen PS, Ross C, Clemmesen KM , et al. Clinical importance of neutralizing antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
33. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24: 1720-1740.
34. Janeway C, et al. Immunobiology. 6th Ed. New York: Garland Science Publishing, 2005.
35. Hausl C, Ahmed RU, Schwartz HP, et al. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood 2004; 104: 115-122.
36. Qian J, Collins M, Sharpe AH, et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-1329.
37. Reipert BM, Sasgary M, Ahmad Ru, et al. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost 2001; 86: 1345-1352.
38. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-2756.
39. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8: 501-507.
40. Martin F, Oliver A, Kearney J. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigen. Immunity 2001; 14: 617-629.
41. McHeyzer-Williams M, McHeyzer-Williams L, Panus J, et al. Helper T-cell-regulated B-cell immunity. Microb Infection 2003; 5: 205-212.
42. Chackerian B, Lenz P, Lowy DR, et al. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002; 169: 6120-6126.
43. Vos Q, Lees A, Wu ZQ, et al. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000; 176: 154-170.
44. Dintzis R, Okajrima M, Middleton MH, et al. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valen. J Immunol 1989; 143: 1239-1244.
45. Wagner CL, Schantz A, Barnathan E, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies. ReoPro and Remicade. Dev Biol (Basel) 2003; 112: 37-53.
46. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Net 1999; 10: 413-422.
47. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8: 23-29.
48. O'Connell NM. Factor XI deficiency from molecular genetics to clinical management. Blood Coagul Fibrinolysis 2003; 14: (Suppl 1): 559-564.
49. Lawler P, White B, Pye S, et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8: 1245-148.
50. Tarnatino M, Aledort L. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors. Transfusion 2001; 41: 1628-1629.
51. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A. mutation type determines risk of inhibitor formation. Thromb and Haemost 1995; 74: 1402-1406.
52. Kemball-Cook G, Tuddenham EGD, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26: 216-219.
53. Oldenburg J, Schroder J, Schmitt C, et al. Small deletion/ insertion mutations within poly-A-runs of factor VIII gene mitigate the severe haemophilia A phenotype. Thromb Haemost 1998; 79: 452-453.
54. Young M, Inaba H, Hoyer LW, et al. Partial correction of a severe molecular defect in haemophilia A, because of errors during expression of the factor VIII gene. Am J Human Genet 1997; 60: 565-573.
55. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-154.
56. Cox G. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 500-504.
57. Aly AM, Aledort LM, Lee TD, et al. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol 1990; 76: 238-241.
58. Frommel D, Allain JP, Saint-Paul E, et al. HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody. Thromb Haemost 1981; 46: 687-689.
59. Lippert LE, Fisher LM, Schook LB. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in haemophilia A. Thromb Haemost 1990; 64: 564-568.
60. Mayr WR, Lechner K, Niessher H, et al. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 1984; 51: 293.
61. Oldenburg J, Pickard JK, Schwang R, et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors to factor VIII. Thromb Haemost 1997; 77: 238-242.
62. Barbosa MDFS, Vielmetter J, Chu S, et al. Clinical link between MHC class II haplotype and interferon -beta (IFN-β immunogenicity. Clin Immunol 2006; 1189: 42-50.
63. Ottesen JL, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 1994; 37: 1178-1185.
64. Fireman P, Fineberg SE, Galloway JA. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care 1982; 5: 119-125.
65. Fineberg SE, Galloway JA, Fineberg NS, et al. Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes 1983; 32: 592-599.
66. Kontsek P, Liptakova H, Kontsekova E. Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects. Acta Virologica 1999; 43: 63-70.
67. Melian EB, Plosker GL. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001; 61: 1661-1691.
68. Du X, Tang JG. Effects of deleting A19 tyrosine from insulin. Biochem Mol Biol Int 1998; 44: 507-513.
69. Stewart TA, Hollingshead PG, Pitts SL, et al. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med 1989; 6: 275-281.
70. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36: 3-10.
71. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
72. Buist MR, Kenemans P, van Kamp GJ, et al. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 1995; 40: 24-30.
73. Tcheng JE, Kereiakes DJ, Lincoff AM. Abciximols readministration: results of RCoPro Readministration Registry. Circulation 2001; 104: 870-875.
74. Baert F, Noman M, Vermeire G, et al. Influence of immunogenicity on the long-term efficicy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
75. Ewensteini BM, Hoots WK, Lusher JM, et al. Inhibition of CD40 ligand (CD154) in the treatment of factor ViII inhibitors. Haematologica 2000; 85: 35-39.
76. Arnold DM, Kelton JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007; 44 (4 Suppl 5): 512-523.
77. Walsh G. Therapeutic insulins and their large scale manufacturer. Appl Microbiol Biotechnol 2005; 67: 151-159.
78. Chu L, Robinson DK. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001; 12: 180-187.
79. Swartz JR Advances in Escherichia coli production of therapeutic proteins. Current Opin Biotechnology 2001; 12: 195-201.
80. Lin Y, Yang X, Chevrier MC, et al. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2005; 10: 459-469.
81. Ettingshausen CE, Kreuz W. Recombinant vs plasma-derived products, especially those with intact vWF, regarding inhibitor dev elopement. Haemophilia 2006; 12 (Suppl 6): 102-106.
82. Gouw SC, van de Bom JG, Auerswald G, et al. Recombinant versus plasma-derived products and the development of inhibitors in previously untreated patients with severe hemophilia A: CANAL cohort study. Blood 2007; 1089: 4693-4697.
83. Goudemand J. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates. Haemophilia 207; 13 (Suppl 5): 47-51.
84. Kisker CT, Eisberg A, Schwartz B; Mononine Study Group. Prophylaxis in factor IX deficiency products and patient variation. Haemophilia 2003; 9: 279-284.
85. Wang L, Zoppe M, Hackeng TM, et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Nat Acad Sci USA 1997; 94: 11564-11566.
86. Hortelano G, Wang L, Xu N, et al. Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia 2001; 7: 207-214.
87. Wen J, Ofosu FA, Hortelano G. Encapsulated primary myoblasts deliver sustained and therapeutic levels of human factor IX to hemophilic mice. J Gene Med 2006; 8: 362-369.
88. Butler M. Animal Cell Culture and Technology, 2nd ed. Oxford. Bios Scientific, 2004.
89. Neusüss C, Demelbauer U, Pelzing M. Glycoform characterization of intact erythropoietin by capillary electrophoresis-electrospray-time of flight-mass spectrometry. Electrophoresis 2005; 26: 1442-1450.
90. Venke S, Gro N-L, Peter T. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98: 3626-3634.
91. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000; 405: 635.
92. Galili U, Shohet SB, Kobrin E, et al. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263: 17755-17762.
93. Restelli V, Butler M. Cell engineering. Springer 2002; 3: 61-92.
94. Brooks S. Appropriate Glycosylation of Recombinant Proteins for Human Use: Implications of Choice of Expression System. Mol Biotechnol 2004; 28: 241-256.
95. Narhi LO, Arakwa T, Aoki, KH, et al. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 1991; 266: 23022-23026.
96. Wasley LC, Timony G, Murtha P, et al. The importance of N-and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 1991; 77: 2624-2632.
97. Storring PL. Assaying glycoprotein hormones - the influence of glycosylation on immunoreactivity. Tren Biotechnol 1992; 10: 427-432.
98. Takeuchi M, Takasai S, Miyazai H, et al. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem 1988; 263: 3657-3663.
99. Goto M, Akai K, Murakami A, et al. Production of recombinant human erythropoietin in mammalian cells: Host-cell dependency of the biological activity of the cloned glycoprotein. Nat Biotechnol 1988; 6: 67-71.
100. Kagawa Y, Takasaki S, Utsumi J, et al.Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. J Biol Chem 1988; 263: 17508-17515.
101. Goochee CF. Bioprocess factors affecting glycoprotein oligosaccharide structure. Dev Biol Stand 1992; 76: 95-104.
102. Sheeley DM, Merrill BM, Taylor LC. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. Anal Biochem 1997; 247: 102-110.
103. Jenkins N, Curling EM. Glycosylation of recombinant proteins: problems and prospects. Enzyme Microb Technol 1994; 16: 354-364.
104. Gawlitzek M, Valley U, Nimtz MM, et al. Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions. J Biotechnol 1995; 42: 117-131.
105. Schweikart F, Jones R, Jaton JC, et al. Rapid structural characterisation of a murine monoclonal IgA alpha chain: heterogeneity in the oligosaccharide structures at a specific site in samples produced in different bioreactor systems. J Biotechnol 1999; 69: 191-201.
106. Curling EM, Hayter PM, Baines AJ, et al. Recombinant human interferon-gamma. Differences in glycosylation and proteolytic processing lead to heterogeneity in batch culture. Biochem J 1990; 272: 333-337.
107. Nyberg GB, Balcarcel RR, Follstad DD, et al. Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells. Biotechnol Bioeng 1999; 62: 336-347.
108. Kinstler O, Molineux G, Treuheit M, et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002; 54: 447-485.
109. Kompella UB, Lee VHL. Pharmacokinetics of peptide and protein drugs. [book auth.] V.H.L. Lee. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 1991: 391.
110. Rabkin R, Dahl DC. Renal uptake and disposal of proteins and peptides. In: Biological Barriers in Protein Delivery. New York: Plenum Press 1993: 299.
111. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. J Clin Pharmacol 2000; 40: 539-551.
112. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Therap Drug Carrier Sys 1992; 9: 249-304.
113. Kartre K. The conjugation of proteins with poly(ethylene glycol) and other polymers. Adv Drug Deliv Rev 1993; 10: 91-114.
114. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54: 459-476.
115. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001; 22: 405-417.
116. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54: 531-545.
117. Savoca KV, Abuchowski, A, Van Es T, et al. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochim Biophys Acta 1979; 578: 47-53.
118. Hershfield, MS, Chaffee S, Koro-Johnson L, et al. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc Nat Acad Sci USA 1991; 88 7185-7189.
119. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long lasting form of interferon: a 40kDa branched poly-ethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconj Chem 2001; 12: 195-202.
120. Reddy KR, Wright TL, Pokros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon a-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.
121. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22: 1383-1391.
122. Chance RE, Root MA, Galloway JA.The immunogenicity of insulin preparations. Acta Endocrinol Suppl 1976; 205: 185-198.
123. Wilson RM, Douglas CA, Tattersall RB, et al. Immunogenicity of highly purified bovine insulin: a comparison with conventional insulins. Diabetologia 1985: 28: 667-670.
124. Stubbe P, Ranke MB, Bierich JR. Incidence of growth hormone antibodies and presumed growth-attenuating antibodies in relation to various pituitary growth hormone preparations. Munich: Urban and Schwarzenberg 1999: 92-99.
125. Wadhwa M, SkogAL, Bird C, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999; 5: 1353-1361.
126. Antonelli G, Simeoni E, Currenti M, et al. Interferon antibodies in patients with infectious diseases. Biotherapy 1997; 107-114.
127. Wang W. Instability, stabilization and formulation of liquid protein pharmaceuticals. Int J Pharmaceut 1999; 185: 129-188.
128. Physician Package Insert Neulasta. Physician Package Insert Neulasta® (Pegfilgrastim) 2003.
129. Reyes N, Ruiz L, Aroche K, et al. Stability of Ala 125 recombinant human interleukin-2 in solution. J Phar Pharmacol 2005; 57: 31-37.
130. Leppert P, Moore WV. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 1980; 51: 691-697.
131. Sharma B. Immunogenicity of therapeutic proteins. Part 2: Impact of container closures. Biotechnol Adv 2007; 25: 318-324.
132. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005; 4: 298-306.
133. Kreilgaard L, Frokjaer S. Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid. Arch Biochem Biophs 1998; 360: 121-134.
134. Krielgaard L, Jones LS, Randolph TW, et al. Effect of tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 1998; 87: 1597-1603.
135. Katakam M, Banga AK. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. Pharma Dev Technol 1997; 2: 143-149.
136. Katakam M, Bell LN, Banga AK. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 1995; 84: 713-716.
137. Bam NB, Cleland JL, Yang J, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharma Sci 1998; 87: 1554-1559.
138. Brange J, Anderson L, Laursen ED, et al. Toward understanding insulin fibrillation. J Pharm Sci 1997; 86: 517-525.
139. Kwon YM, Boudys M, Knutson K, et al. In situ study of insulin aggregation induced by water-organic solvent interface. Pharm Res 2001; 18: 1754-1759.
140. Bam NB, Randolph TW, Cleland JL. Stability of protein formulations: investigation of surfactant effects by a novel EPR spectroscopic technique. Pharm Res 1995; 12: 2-11.
141. Webb SD, Cleland JL, Carpenter JF. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J Pharm Sci 002; 91: 543-558.
142. Webb SD, Golledge SL, Cleland JL, et al. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations. J Pharm Sci 2002; 91: 1474-1487.
143. Maa YF, Hsu CC. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol Bioeng 1997; 54: 503-512.
144. Treuheit MJ, Kosky AA and Brems DN. Inverse relationship of protein concentration and aggregation. Pharm Res 2002; 19: 511-516.
145. Sadhale Y, Shah JC. Stabilization of insulin against agitation-induced aggregation by the GMO cubic phase gel. Int J Pharm 1999; 191: 51-64.
146. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997; 17: S15-21.
147. Emily HA, Wei W, John W. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 2002; 91: 2252-2264.
148. Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 1997; 86: 1250-1255.
149. Johnston TP. Adsorption of recombinant human granulocyte colony stimulating factor (rhG-CSF) to polyvinyl chloride, polypropylene, and glass: effect of solvent additives. PDA J Pharm Sci Tech 1996; 50: 238-245.
150. Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci 2005; 94: 918-927.
151. Mizutani T. Decreased activity of proteins absorbed onto glass surfaces with porous glass as a reference. J Pharm Sci 1980; 69: 279-282.
152. Sharma B. Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes. Biotechnol Adv 2007; 25: 325-331.
153. Sharma B. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex®. Eur J Hosp Pharm 2004; 5: 86-91.
154. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Drug Carrier Sys 1993; 10: 307-377.
155. Shihong L, Christian S, Borchardt, R. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol and Bioeng 1995; 48: 490-500.
156. Hermeling, S, Crommelin DJ, Schellekens H, et al. Structure- immunogenicity relationships of therapeutic proteins. Pharma Res 2004; 21: 897-903.
157. Ross C, Clemmensen KM, Svenson M , et al. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000; 48: 706-712.
158. Fineberg SE, Kawabata T, Finio-Kent, et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and II inhaled insulin (Exubera) trials and a two-year extension. J Clin Endocrinol Metab 2005; 90: 3287-3294.